A Phase 3 Study of Patidegib Gel 2% to Treat Persistent Basal Cell Carcinoma in People with Gorlin Syndrome

Full Title

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Gorlin Syndrome (WIRB)

Purpose

People with the genetic disorder Gorlin syndrome often develop skin cancers called basal cell carcinoma (BCC) on their faces. Researchers want to see if patidegib gel works well for reducing BCCs in people with Gorlin syndrome.

If you join this study, you will be randomly assigned to receive patidegib gel 2% or a placebo (inactive) gel.

Who Can Join

To join this study, there are a few conditions. You must:

• Have Gorlin syndrome with a mutation in the PTCH1 gene.
• Have at least 10 BCC lesions on your face when you start the study.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Anthony Rossi’s office at 646-608-2342.